Loading...
•
Jun 30, 2021
CRISPR Therapeutics Q2 2021 Earnings Report
Reported notable data from hemoglobinopathies program while rapidly advancing clinical and pre-clinical portfolio and capabilities.
Key Takeaways
CRISPR Therapeutics reported a strong second quarter, highlighted by a $900 million upfront payment from Vertex related to their collaboration agreement. The company is progressing its clinical programs, including CTX001 for hemoglobinopathies, and anticipates reporting clinical data from immuno-oncology programs later in the year.
More than 45 patients have been dosed with CTX001 across CLIMB-Thal-111 and CLIMB-SCD-121 to date; completion of enrollment in both trials is expected in 2021
Received Orphan Drug Designation (ODD) for Phase 1 clinical trial of CTX130™ for the treatment of T-cell lymphoma
Enrollment ongoing in CTX110™, CTX120™ and CTX130 clinical trials
Vertex made a $900 million upfront payment to CRISPR Therapeutics in connection with the completion of the transaction in June
Revenue by Segment
Forward Guidance
The Company expects to report additional clinical data in 2021 from its ongoing Phase 1 CARBON trial assessing the safety and efficacy of several dose levels of CTX110, its wholly-owned allogeneic chimeric antigen receptor T cell (CAR-T) investigational therapy targeting CD19, for the treatment of relapsed or refractory B-cell malignancies. The Company expects to report top-line data from CTX120 and CTX130 trials in 2021.
Positive Outlook
- Expects to report additional clinical data in 2021 from its ongoing Phase 1 CARBON trial assessing the safety and efficacy of several dose levels of CTX110
- CRISPR Therapeutics’ Phase 1 clinical trial assessing the safety and efficacy of several dose levels of CTX120 is ongoing and expects to report top-line data from this trial in 2021
- CRISPR Therapeutics’ two independent Phase 1 clinical trials assessing the safety and efficacy of several dose levels of CTX130 are ongoing and expects to report top-line data from these trials in 2021
- CRISPR Therapeutics and its partner ViaCyte remain on track to initiate a Phase 1/2 trial of their allogeneic stem cell-derived therapy for the treatment of Type 1 diabetes in 2021
- The Company expects to move multiple programs utilizing in vivo approaches into the clinic in the next 18 to 24 months
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...